Intravitreal bevacizumab for treatment‐naïve subfoveal occult choroidal neovascularization in age‐related macular degeneration
- 26 May 2009
- journal article
- Published by Wiley in Acta Ophthalmologica
- Vol. 87 (4) , 404-407
Abstract
: Purpose: This study aimed to evaluate the efficacy of multiple injections of intravitreal bevacizumab for treatment‐naïve subfoveal occult choroidal neovascularization (CNV) in age‐related macular degeneration (AMD).Methods: Twelve eyes of 12 patients (mean age 76 ± 6 years) with mean best corrected visual acuity (BCVA) of 20/100 and occult subfoveal CNV at fluorescein angiography (FA), indocyanine‐green (ICG) angiography and optical coherence tomography (OCT), showing intra‐ or subretinal fluid with or without retinal pigment epithelial detachment (PED), underwent multiple intravitreal injections (mean 2.4 ± 0.7) of 1.25 mg (0.05 ml) bevacizumab. Visual acuity and OCT findings were assessed at the end of follow‐up.Results: After a mean follow‐up of 5.7 ± 2 months, BCVA improved from 20/100 (range 20/50–20/303) to 20/60 (range 20/28–20/200) (p = 0.038). Five eyes (42%) increased BCVA by ≥ 3 lines, six eyes (50%) increased BCVA by < 3 lines and one eye (8%) remained stable. Macular thickness decreased from 298 ± 71 μm to 223 ± 72 μm (p = 0.017). No ocular or systemic side‐effects were observed.Conclusions: Short‐term results suggest that multiple intravitreal injections of 1.25 mg bevacizumab are well tolerated and associated with significant improvements in BCVA and decreased retinal thickness by OCT in most patients with treatment‐naïve occult CNV. Further evaluation of intravitreal bevacizumab for the treatment of occult CNV is warranted.Keywords
This publication has 20 references indexed in Scilit:
- INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2007
- INTRAVITREAL BEVACIZUMAB FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATIONRetina, 2007
- COMBINED PHOTODYNAMIC THERAPY WITH VERTEPORFIN AND INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- VISUAL IMPROVEMENT FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) IN EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressureActa Ophthalmologica Scandinavica, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age‐related macular degenerationActa Ophthalmologica Scandinavica, 2006
- Decimals in data valuesActa Ophthalmologica Scandinavica, 2006
- Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2006
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005